Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Gains No Impartiality Benefit From Conflict-Of-Interest Policy, Advocates Say

Executive Summary

Friends of Cancer Research cites an FDA-sponsored study to argue that agency adherence to an advisory committee conflict-of-interest policy that is stricter than required by law does not increase the impartiality of panel members’ recommendations.

You may also be interested in...



Conflict-Of-Interest Policy Relaxation For FDA Cmtes. Could Be Easy PDUFA Add-on

FDA Commissioner Margaret Hamburg’s willingness to explore changes in conflict-of-interest policies for advisory committee members, coupled with a push for reforms by industry and lawmakers, suggests a relaxation of current screening requirements could become an easy add-on to the Prescription Drug User Fee Act reauthorizing legislation in 2012.

FDA Advisory Committee Waivers Reflect Recruitment Challenges

Recent waivers allowing the participation of outside experts at drug-related advisory committee meetings reflect FDA's difficulties in finding qualified individuals to provide advice on specialized topics.

Conflict-Of-Interest Policy Relaxation For FDA Cmtes. Could Be Easy PDUFA Add-on

FDA Commissioner Margaret Hamburg’s willingness to explore changes in conflict-of-interest policies for advisory committee members, coupled with a push for reforms by industry and lawmakers, suggests a relaxation of current screening requirements could become an easy add-on to the Prescription Drug User Fee Act reauthorizing legislation in 2012.

Related Content

Topics

UsernamePublicRestriction

Register

PS053642

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel